Trimethoprim-sulfamethoxazole induced rash and fatal hematologic disorders

Area of Science:

• Pharmacology
• Hematology
• Infectious Diseases

Background:

• Trimethoprim-sulfamethoxazole (TMP-SMX) is a widely prescribed antibiotic combination.
• Adverse drug reactions (ADRs) affect 6-8% of patients, commonly causing mild gastrointestinal or cutaneous symptoms.
• Hematological abnormalities are less common but serious potential side effects of TMP-SMX.

Observation:

• A 40-year-old male developed severe neutropenia, thrombocytopenia, generalized rash, and oral candidiasis after a 5-day course of TMP-SMX.
• While rash is a known side effect, the combination of severe hematological issues and candidiasis was rare.
• The patient's condition rapidly deteriorated despite supportive treatments including transfusions and filgrastim.

Findings:

• TMP-SMX can precipitate life-threatening hematological complications, including severe neutropenia and thrombocytopenia.
• The co-occurrence of generalized rash and oral candidiasis alongside these hematological issues indicates a severe systemic reaction.
• Despite aggressive medical intervention, the patient's condition proved fatal, underscoring the potential severity of TMP-SMX-induced ADRs.

Implications:

• Clinicians must maintain a high index of suspicion for severe hematological ADRs with TMP-SMX, even in the absence of typical symptoms.
• Early recognition and management of TMP-SMX-induced hematological abnormalities are critical, though outcomes can be poor.
• This case emphasizes the need for careful patient monitoring and consideration of alternative treatments when managing infections in patients at risk for severe drug reactions.